Page 25 - GPD-4-3

Gene & Protein in Disease Targeting cathepsins during cancer development

doi: 10.3109/10428194.2015.1030638 129. Lee EF, Czabotar PE, van Delft MF, et al. A novel BH3 ligand
that selectively targets Mcl-1 reveals that apoptosis can proceed
118. Debrincat MA, Pleines I, Lebois M, et al. BCL-2 is
dispensable for thrombopoiesis and platelet survival. Cell without Mcl-1 degradation. J Cell Biol. 2008;180(2):341-355.
Death Dis. 2015;6(4):e1721. doi: 10.1083/jcb.200708096
doi: 10.1038/cddis.2015.97 130. Lee EF, Czabotar PE, Yang H, et al. Conformational changes
in Bcl-2 pro-survival proteins determine their capacity to
119. Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed bind ligands. J Biol Chem. 2009;284(44):30508-30517.
anuclear cell death delimits platelet life span. Cell.
2007;128(6):1173-1186. doi: 10.1074/jbc.M109.040725
doi: 10.1016/j.cell.2007.01.037 131. Nakao S, Zandi S, Sun D,Hafezi-Moghadam A. Cathepsin
B-mediated CD18 shedding regulates leukocyte recruitment
120. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 from angiogenic vessels. FASEB J. 2018;32(1):143-154.
with venetoclax in relapsed chronic lymphocytic leukemia.
N Engl J Med. 2016;374(4):311-322. doi: 10.1096/fj.201601229R
doi: 10.1056/NEJMoa1513257 132. Oskarsson T. Extracellular matrix components in breast cancer
progression and metastasis. Breast. 2013;22(Suppl 2):S66-S72.
121. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent
and selective BCL-2 inhibitor, achieves antitumor activity doi: 10.1016/j.breast.2013.07.012
while sparing platelets. Nat Med. 2013;19(2):202-208. 133. Wang B, Sun J, Kitamoto S, et al. Cathepsin S controls
doi: 10.1038/nm.3048 angiogenesis and tumor growth via matrix-derived
angiogenic factors. J Biol Chem. 2006;281(9):6020-6029.
122. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax
in relapsed or refractory chronic lymphocytic leukaemia doi: 10.1074/jbc.M509134200
with 17p deletion: A multicentre, open-label, phase 2 study. 134. Guinec N, Dalet-Fumeron V, Pagano M. “In vitro” study
Lancet Oncol. 2016;17(6):768-778. of basement membrane degradation by the cysteine
doi: 10.1016/S1470-2045(16)30019-5 proteinases, cathepsins B, B-like and L. Digestion of collagen
IV, laminin, fibronectin, and release of gelatinase activities
123. Tahir SK, Smith ML, Hessler P, et al. Potential mechanisms from basement membrane fibronectin. Biol Chem Hoppe
of resistance to venetoclax and strategies to circumvent it. Seyler. 1993;374(12):1135-1146.
BMC Cancer. 2017;17(1):399.
doi: 10.1515/bchm3.1993.374.7-12.1135
doi: 10.1186/s12885-017-3383-5
135. Mai J, Sameni M, Mikkelsen T, Sloane BF. Degradation of
124. Koehler MF, Bergeron P, Choo EF, et al. Structure-guided extracellular matrix protein tenascin-C by cathepsin B: An
rescaffolding of selective antagonists of BCL-XL. ACS Med interaction involved in the progression of gliomas. Biol
Chem Lett. 2014;5(6):662-667. Chem. 2002;383(9):1407-1413.
doi: 10.1021/ml500030p doi: 10.1515/BC.2002.159

125. Lessene G, Czabotar PE, Sleebs BE, et al. Structure-guided 136. Felbor U, Dreier L, Bryant RA, Ploegh HL, Olsen BR,
design of a selective BCL-X(L) inhibitor. Nat Chem Biol. Mothes W. Secreted cathepsin L generates endostatin from
2013;9(6):390-397. collagen XVIII. EMBO J. 2000;19(6):1187-1194.
doi: 10.1038/nchembio.1246 doi: 10.1093/emboj/19.6.1187
126. Tao ZF, Hasvold L, Wang L, et al. Discovery of a potent and 137. Veillard F, Saidi A, Burden RE et al. Cysteine cathepsins S
selective BCL-XL inhibitor with in vivo activity. ACS Med and L modulate anti-angiogenic activities of human
Chem Lett. 2014;5(10):1088-1093. endostatin. J Biol Chem. 2011;286(43):37158-37167.
doi: 10.1021/ml5001867 doi: 10.1074/jbc.M111.284869
127. Wei G, Margolin AA, Haery L, et al. Chemical genomics 138. Gineyts E, Bonnet N, Bertholon C, et al. The C-terminal
identifies small-molecule MCL1 repressors and Bcl-xL as intact forms of periostin (iPTN) are surrogate markers
a predictor of MCL1 dependency. Cancer Cell. 2012;21(4): for osteolytic lesions in experimental breast cancer bone
547-562. metastasis. Calcif Tissue Int. 2018;103(5):567-580.
doi: 10.1016/j.ccr.2012.02.028 doi: 10.1007/s00223-018-0444-y
128. Wertz IE, Kusam S, Lam C, et al. Sensitivity to antitubulin 139. Podgorski I, Linebaugh BE, Koblinski JE, et al. Bone marrow-
chemotherapeutics is regulated by MCL1 and FBW7. derived cathepsin K cleaves SPARC in bone metastasis. Am
Nature. 2011;471(7336):110-114. J Pathol. 2009;175(3):1255-1269.
doi: 10.1038/nature09779 doi: 10.2353/ajpath.2009.080906

Volume 4 Issue 3 (2025) 14 doi: 10.36922/gpd.4768